GeneFerm Biotechnology Co., Ltd. develops, manufactures, markets, and sells fermented products in Taiwan and internationally. More Details
Mediocre balance sheet with questionable track record.
Share Price & News
How has GeneFerm Biotechnology's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1796 is less volatile than 75% of TW stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: 1796's weekly volatility (4%) has been stable over the past year.
7 Day Return
TW Personal Products
1 Year Return
TW Personal Products
Return vs Industry: 1796 exceeded the TW Personal Products industry which returned -8% over the past year.
Return vs Market: 1796 underperformed the TW Market which returned 48.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is GeneFerm Biotechnology's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StGeneFerm Biotechnology (GTSM:1796) Takes On Some Risk With Its Use Of Debt
3 months ago | Simply Wall StWill GeneFerm Biotechnology (GTSM:1796) Multiply In Value Going Forward?
Is GeneFerm Biotechnology undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 1796's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 1796's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 1796 is poor value based on its PE Ratio (46.2x) compared to the TW Personal Products industry average (15.5x).
PE vs Market: 1796 is poor value based on its PE Ratio (46.2x) compared to the TW market (17.7x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 1796's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 1796 is good value based on its PB Ratio (1.9x) compared to the TW Personal Products industry average (2.2x).
How is GeneFerm Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Household industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as GeneFerm Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has GeneFerm Biotechnology performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1796 has high quality earnings.
Growing Profit Margin: 1796 became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: 1796's earnings have declined by 65% per year over the past 5 years.
Accelerating Growth: 1796 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 1796 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Personal Products industry (4.7%).
Return on Equity
High ROE: 1796's Return on Equity (3.1%) is considered low.
How is GeneFerm Biotechnology's financial position?
Financial Position Analysis
Short Term Liabilities: 1796's short term assets (NT$806.4M) exceed its short term liabilities (NT$408.1M).
Long Term Liabilities: 1796's short term assets (NT$806.4M) exceed its long term liabilities (NT$167.0M).
Debt to Equity History and Analysis
Debt Level: 1796's debt to equity ratio (57%) is considered high.
Reducing Debt: 1796's debt to equity ratio has increased from 25.8% to 57% over the past 5 years.
Debt Coverage: 1796's debt is not well covered by operating cash flow (15.7%).
Interest Coverage: 1796's interest payments on its debt are well covered by EBIT (4.2x coverage).
What is GeneFerm Biotechnology current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 1796's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 1796's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 1796's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 1796's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 1796 is not paying a notable dividend for the TW market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1796's dividend in 3 years as they are not forecast to pay a notable one for the TW market.
How experienced are the management team and are they aligned to shareholders interests?
GeneFerm Biotechnology has no CEO, or we have no data on them.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 44.9%.
GeneFerm Biotechnology Co., Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: GeneFerm Biotechnology Co., Ltd.
- Ticker: 1796
- Exchange: TPEX
- Founded: 1999
- Industry: Personal Products
- Sector: Household
- Market Cap: NT$1.354b
- Shares outstanding: 40.42m
- Website: https://www.geneferm.com
- GeneFerm Biotechnology Co., Ltd.
- Nangang Software Park
- Building F, 4F-3
- Taipei City
GeneFerm Biotechnology Co., Ltd. develops, manufactures, markets, and sells fermented products in Taiwan and internationally. The company offers a range of raw materials, such as fermented microbial, fungi...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/22 08:30|
|End of Day Share Price||2021/06/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.